Range Financial Group LLC Has $1.51 Million Stake in Gilead Sciences, Inc. $GILD

Key Points

• Range Financial Group LLC reduced its stake in Gilead Sciences by 14.9%, selling 2,369 shares, resulting in holdings worth approximately $1.5 million.
• Insider sales included Johanna Mercier selling 28,000 shares valued at over $3.3 million and CEO Daniel Patrick O'Day selling 10,000 shares for about $1.14 million.
• Gilead recently announced a quarterly dividend of $0.79 per share, with an upcoming pay date on September 29th, representing a 2.8% yield.

Range Financial Group LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,582 shares of the biopharmaceutical company's stock after selling 2,369 shares during the period. Range Financial Group LLC's holdings in Gilead Sciences were worth $1,506,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GILD. Ariel Investments LLC raised its stake in Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares during the period. Swedbank AB boosted its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after acquiring an additional 16,663 shares in the last quarter. Focus Partners Wealth increased its stake in Gilead Sciences by 21.2% in the first quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock valued at $15,986,000 after acquiring an additional 24,930 shares during the period. Finally, ASR Vermogensbeheer N.V. bought a new stake in Gilead Sciences in the first quarter valued at about $11,688,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Up 0.4%

Gilead Sciences stock traded up $0.47 during midday trading on Friday, hitting $114.09. 12,580,487 shares of the stock were exchanged, compared to its average volume of 5,841,828. The company has a fifty day simple moving average of $114.10 and a two-hundred day simple moving average of $110.06. Gilead Sciences, Inc. has a 52 week low of $81.83 and a 52 week high of $121.83. The stock has a market capitalization of $141.56 billion, a PE ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm earned $2.01 EPS. Gilead Sciences's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock worth $9,390,030. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of several recent research reports. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.